Charles River Laboratories International, Inc. CRL

292.84 (1.60) (0.54%) as of 25 Sep
Market cap
$14.1B
P/E
0.0×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month

Charles River Laboratories International, Inc. (CRL) P/S ratio

As of 25 September 2026, Charles River Laboratories International, Inc. (CRL) trades at a P/S ratio of 3.5×. Over the past ten years it has ranged from 1.3× (April 2025) to 7.0× (September 2021); the current reading is higher than 85% of that period. That is below the Diagnostics & Research industry median of 4.9× and below the Healthcare sector median of 3.8×.

P/S ratio, daily

Annual

Period P/S ratio Change
FY2025 2.5× 5.14%
FY2024 2.3× (19.41%)
FY2023 2.9× 4.12%
FY2022 2.8× (47.86%)
FY2021 5.4× 26.42%
FY2020 4.2× 49.10%
FY2019 2.8× 18.59%
FY2018 2.4× (15.33%)
FY2017 2.8× 32.18%
FY2016 2.1× (21.95%)

Quarterly

Period P/S ratio Change
Jun 2026 2.7× 29.88%
Mar 2026 2.1× (14.84%)
Dec 2025 2.5× 28.67%
Sep 2025 1.9× 3.38%
42 more quarters

Against its own ten years

Low 1.3× High 7.0×
Ten-year median 2.7×
Current reading's percentile 85

P/S ratio against peers

Company P/S ratio
ICLR ICON PLC compare 1.6×
LH Labcorp Holdings Inc. compare 1.8×
DGX Quest Diagnostics Incorporated compare 2.3×
CRL Charles River Laboratories International, Inc. 3.5×
QGEN QIAGEN N.V. compare 4.3×
RVTY Revvity Inc. compare 5.8×
MEDP Medpace Holdings, Inc. compare 6.3×
GH Guardant Health, Inc. compare 19.9×
TWST Twist Bioscience Corporation compare 26.5×
Diagnostics & Research industry median 4.9×
Healthcare sector median 3.8×
Market median 2.0×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

More on CRL